Tirzepatide activates both the GLP-1 and GIP receptors, which help control blood sugar levels and reduce hunger. This dual-action mechanism promotes fat loss, stabilizes energy, and supports better metabolic health.

It’s a simple, once-weekly subcutaneous (under-the-skin) injection—typically in the abdomen, thigh, or upper arm. Most patients self-administer the dose after being shown proper technique by a licensed provider.

Many patients notice reduced appetite and gradual weight loss within the first few weeks. Significant results are typically seen after 8–12 weeks, depending on dose and lifestyle factors.

The most common side effects are mild and temporary, such as nausea, stomach upset, or fatigue. These usually improve as your body adjusts. Your provider will monitor your progress and adjust dosing as needed.

Tirzepatide is generally well-tolerated but may not be suitable for individuals with certain medical conditions, such as a history of medullary thyroid carcinoma or pancreatitis. Always consult your healthcare provider to determine if it’s right for you.